ReviewWorld journal of gastrointestinal oncology2020
Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines.
Review in World journal of gastrointestinal oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Global hotspots and trends in the application of neoadjuvant therapy for gastric cancer: a bibliometric analysis.Frontiers in oncology · 2026Pooled it
- Skeletal Muscle Change During Neoadjuvant Therapy and Its Impact on Prognosis in Patients With Gastrointestinal Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers.World journal of gastrointestinal oncology · 2024Trial
- Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.The British journal of radiology · 2021Trial
- The prognostic value of log odds of positive lymph nodes in patients with resectable locally advanced gastric cancer following neoadjuvant therapy: results from the SEER database.Translational cancer research · 2026Article
- CT-based delta-radiomics nomogram to assess tumor regression grade in locally advanced gastric cancer patients following neoadjuvant chemotherapy.Abdominal radiology (New York) · 2026Article
- A Radiomics-Clinical Nomogram for Pre-Treatment Prediction of Neoadjuvant Chemotherapy Response in Locally Advanced Gastric Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Hematological biomarkers for predicting pathologic response to neoadjuvant immunochemotherapy and cycle optimization in locally advanced gastric cancer.Frontiers in immunology · 2026Article
- FLOT vs DOS neoadjuvant chemotherapy in locally advanced gastric cancer: propensity score analysis.International journal of clinical oncology · 2025Article
- Article
- Modified RECIST submodels and ordinal regression model predict neoadjuvant chemoimmunotherapy response in locally advanced gastric cancer.Scientific reports · 2025Article
- Gastrectomy after neoadjuvant chemotherapy in five cases of locally advanced gastric cancer with pancreatic head invasion.International cancer conference journal · 2025Article
- Factors influencing pathological response after neoadjuvant therapy for advanced gastric cancer.American journal of translational research · 2025Article
- Conditional Survival Rate of Patients Undergoing Gastrectomy with D2 Lymph Node Dissection After Neoadjuvant Chemotherapy: A Retrospective Study.International journal of general medicine · 2025Article
- Deep learning nomogram for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer patients.Abdominal radiology (New York) · 2024Article
- Diagnostic Potential ofInternational journal of molecular sciences · 2024Article
- Intratumoral and peritumoral radiomics predict pathological response after neoadjuvant chemotherapy against advanced gastric cancer.Insights into imaging · 2024Article
- Comparison of the predictive value of pathological response at primary tumor and lymph node status after neoadjuvant chemotherapy in locally advanced gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer.BMC cancer · 2023Article
- Prognostic significance of preoperative serum tumor markers in hepatoid adenocarcinoma of stomach (HAS).BMC cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is one of the most common digestive system tumors in China, and locally advanced gastric cancer (LAGC) accounts for a high proportion of newly diagnosed cases. Although surgery is the main treatment for gastric cancer, surgical excision alone cannot achieve satisfactory outcomes in LAGC patients. Neoadjuvant therapy (NAT) has gradually become the standard treatment for patients with LAGC, and this treatment can not only achieve tumor downstaging and improve surgical rate and the R0 resection rate, but it also significantly improves the long-term prognosis of patients. Peri/preoperative neoadjuvant chemotherapy and preoperative chemoradiotherapy are both recommended according to a large number of studies, and the regimens have also been evolved in the past decades. Since the NCCN guidelines for gastric cancer are one of the most authoritative evidence-based guidelines worldwide, here, we demonstrate the development course and major breakthroughs of NAT for gastric cancer based on the vicissitudes of the NCCN guidelines from 2007 to 2019, and also discuss the future of NAT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.